Markman Advisors
Patent Valuation, Monetization and Investments

News

Markman Publications

part5.png

The members of Markman Advisors publish and are quoted frequently within the media.  We have appeared in The Wall Street Journal, Bloomberg, Nature BiotechnologyIAM, The Patent Investor, IPWatchdog, Above The Law, among others.  See our Press page for a full listing of our appearances within the press.

Markman Advisors has frequently “broken” patent news through its Twitter account.  Our Twitter feed has been picked up by numerous financial news outlets, including Bloomberg, Reuters, TheStreet, Yahoo Finance, SeekingAlpha, among others.

The members of Markman Advisors have each been selected to the IAM Strategy 300 for both 2015 and 2016, recognizing professionals top 300 World's Leading IP Strategists with an established track record in developing and rolling out world-class IP value creation programs.


Even if IPRs are deemed unconstitutional, not much will change - except for pharma sector, which will hate it
Jun 23, 2017, IAM Blog, See publication

IPR Oral Argument Rules Offer Opportunities, Pitfalls
Jun 22, 2017, Law 360 - Intellectual Property, See publication

Is TC Heartland All Good News for Patent Litigation Defendants?
Jun 7, 2017, IPWatchdog, See publication

Quoted - Regeneron, Sanofi urge court to reverse ban on cholesterol drug
Jun 6, 2017, Reuters, See publication

Amgen v. Regeneron: Will the permanent injunction against Regeneron’s new PCSK9-inhibitor hold up on appeal?
Jan 17, 2017, IPWatchdog, See publication

Apparent Settlement Authority In A Paragraph IV Dispute
Jan 10, 2017, Law 360, See publication

Quoted -- Going Mainstream: Will Blockchain's Open-Source Ethos Survive Corporate America?
Oct 16, 2016, Law 360 - In Depth, See publication

After the CAFC's Planet Blue decision early Alice motions may now fade away
Sep 16, 2016, IAM Media, See publication

Quoted - Nine months and counting for keenly awaited CAFC software patent 101 decision
Sep 8, 2016, IAM Blog, See publication

Quoted - Automobile technology sector seen as target of possible patent war
Apr 28, 2016, The Patent Investor, See publication

Quoted - Janssen Biotech requests expedited trial in Remicade patent dispute with Celltrion
Apr 14, 2016, The Patent Investor, See publication

Quoted - Patent investors are pursuing trading strategy around patent disputes over biologics
Mar 31, 2016, The Patent Investor, See publication

Quoted - Panel Recommends FDA Approval of Remicade Knockoff
Feb 9, 2016, Wall Street Journal, See publication

McRo decision expected to clarify abstract idea doctrine under Alice
Jan 5, 2016, IP Watchdog, See publication

Big pharma scores first victory in IPR battle with Bass and Spangenberg, but the war is far from over
Aug 27, 2015, IAM Media, See publication

The Kyle Bass pharma patent IPR strategy looks to be a lot more sophisticated and long-term than many think
Jul 17, 2015, IAM Media, See publication

A 1st Look At PTAB's Plan For Overlapping Proceedings
July 14, 2015, Law 360, See publication

Inter-Partes Review: America’s Patent Litigation Game-Changer
Nov 2014, The Patent Lawyer Magazine

When Jury's Verdict Is Not The End Of Patent Damages Case
Sep. 17, 2013, Law 360, See publication

Isolating The DNA of Patent Damages
July 1, 2013, Law 360, See publication

No blog posts yet.